CLL

Pirtobrutinib has shown improved progression-free survival compared with bendamustine plus rituximab in patients with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma. The finding suggests the BTK inhibitor may become a new first-line option for blood cancer patients, and oncologists are weighing what it means for existing standard-of-care treatment choices.